期刊文献+

含利福平固定剂量复合抗痨药物的现实和前景——国际防痨和肺病联合会(IUATLD)和世界卫生组织(WHO)结核病规程小组联合声明 被引量:4

The promise and reality of fixed-dose combinations with rifampicin A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis programme of the World Health Organization
下载PDF
导出
摘要 1993年10月5日经国际防痨和肺病联合会执行委员会和理事会批准。全球范围的结核病的恶化已有了广泛的和精确的报告,并成为人们主要关注的问题。结核菌同时对异烟肼和利福平以及对其他药物耐药性的增多的事实已被提为全球公共卫生的紧迫事件。结核病中对药物的耐药性常由于不合理方案和不规则用药所致,实际上是单一治疗所造成的。
作者 张立兴
出处 《国际结核病与肺部疾病杂志》 1995年第1期14-15,共2页 The International Journal of Tuberculosis and Lung Disease
  • 相关文献

参考文献9

  • 1World Health Organization Tuberculosis Programme.Treatmentof tuberculosis: guidelines for national programmes. . 1993
  • 2Fox W.Drug combinations and the bioavailability of rifampicin. Tubercle . 1990
  • 3Acocella G.Studies of bioavailability in man. Bull Int Unton Tuberc Lung Dis . 1989
  • 4Ellard G A,Ellard D R,Allen B W et al.The bioavailability of isoniazid, rifampicin and pyrazinamide in two commercially available combined formulatons designed for use in the short-course treatment of tuberculosis. The American Review of Respiratory Disease . 1986
  • 5Geiter LJ,O‘Brien JR,Combs DL,Snider DE.United States Publi cHealth Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combined tabler of isoniazid, rifampin and pyrazinamide. Tubercle . 1987
  • 6International Union Against Tuberculosis and Lung Disease.Antituberculosis regimens of chemotherapy.Recommendations from the Committee on Treatment of the IUATLD. Bulletin of the International Union Against Tuberculosis . 1988
  • 7World Health Organization.Certification scheme on the quality of pharmaceutical products moving in international commerce. . 1993
  • 8Editorial.Multi-drug formulations. Ind-Tuberc . 1988
  • 9World Health Organization.World Health Assembly. . 1992

共引文献1

同被引文献16

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部